Recommended design features of future clinical trials of antibacterial agents for Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 1, 2010, Pages

  Spellberg, Brad ^a,b   Talbot, George ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Talbot Advisors   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION; FOOD AND DRUG ADMINISTRATION; HOSPITAL ACQUIRED BACTERIAL PNEUMONIA; HOSPITAL INFECTION; HUMAN; LABORATORY TEST; LUNG LAVAGE; MICROBIOLOGICAL EXAMINATION; MORTALITY; NONHUMAN; PEDIATRICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; STUDY DESIGN; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA; BIOASSAY; CLINICAL TRIAL (TOPIC); CROSS INFECTION; HOSPITAL; METHODOLOGY; PATIENT SELECTION; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; UNITED STATES;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; ENDPOINT DETERMINATION; HOSPITALS; HUMANS; PATIENT SELECTION; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955698205     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653065     Document Type: Conference Paper

References (101)

1. Emori TG, Banerjee SN, Culver DH, et al. Nosocomial infections in elderly patients in the United States, 1986-1990. National Nos-ocomial Infections Surveillance System. Am J Med 1991; 91:289S-293S.
2. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274:639-644.
3. Richards MJ, Edwards JR, Culver DH, Gay-nes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892.
4. McEachern R, Campbell GD Jr. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am 1998; 12:761-779.
5. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45:1179-1181.
6. Munoz-Price LS, Weinstein RA. Acinetobac-ter infection. N Engl J Med 2008; 358: 1271-1281.
7. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitali-zation. Emerg Infect Dis 2007; 13:97-103.
8. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Che-mother 2007; 59:772-774.
9. Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect 2007; 13:117-119.
10. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29:630-636.
11. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudo-monas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(Suppl 2):S43-S48.
12. McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006; 119: S29-S36; discussion S62-S70.
13. McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 2006; 42(Suppl 2):S65-S71.
14. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imi-penem resistance among Pseudomonas aeru-ginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900.
15. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacoth-erapy 2005; 25:1353-1364.
16. Jones R. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S81-S87 (in this supplement).
17. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-164.
18. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
19. Spellberg B, Fleming TR, Gilbert DN. Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 47(Suppl 3):S105-S107.
20. Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert D. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis 2008; 47(S3):S249-S265.
21. Guidance for Industry. Community-acquired bacterial pneumonia: developing drugs for treatment. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2009:24-25. http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/ Guid-ances/ucm123686.pdf. Accessed 1 March 2010.
22. Spellberg B, Talbot GH, Boucher HW, et al.; Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Antimicrobial agents for complicated skin and skin structure infections: justification of non-inferiority margins in the absence of placebo-controlled trials. Clin Infect Dis 2009; 49: 383-391.
23. Laessig K. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: Food and Drug Administration perspective. Clin Infect Dis 2010; 51(Suppl 1):S117-S119 (in this supplement).
24. Sorbello A. Registration trials of antibacterial drugs for the treatment of nosocomial pneumonia. Clin Infect Dis 2010; 51(Suppl 1): S36-S41 (in this supplement).
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E10, choice of control group and related issues in clinical trials. 1998. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125912.pdf. Accessed 1 March 2010.
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E9, statistical principles for clinical trials. 1998. http://www.emea.europa.eu/ pdfs/human/ich/036396en.pdf. Accessed 1 March 2010.
27. Guidance for Industry. Antibacterial drug products: use of noninferiority studies to support approval. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2007. http://www.fda.gov/down loads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/ucm 070951.pdf. Accessed 1 March 2010.
28. Celis R, Torres A, Gatell JM, Almela M, Rod-riguez-Roisin R, Agusti-Vidal A. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93:318-324.
29. Clec'h C, Timsit JF, De Lassence A, et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004; 30:1327-1333.
30. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-362.
31. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-268.
32. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281-287.
33. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-420.
34. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007; 35:379-385.
35. Leroy O, Meybeck A, d'Escrivan T, Devos P, Kipnis E, Georges H. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003; 29: 2170-2173.
36. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27:158-164.
37. Ruiz M, Torres A, Ewig S, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000; 162:119-125.
38. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator- associated pneumonia: a pilot study. Am J Respir Crit Care Med 1998; 157: 371-376.
39. Teixeira PJ, Seligman R, Hertz FT, Cruz DB, Fachel JM. Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. J Hosp Infect 2007;65: 361-367.
40. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
41. Niederman M. Hospital-acquired pneumonia, health care-associated pneumonia, community-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis 2010; 51(Suppl 1):S12-S17 (in this supplement).
42. File T. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines. Clin Infect Dis 2010; 51(Suppl 1): S42-S47 (in this supplement).
43. Chastre J. Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired and/or ventilator-associated pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S54-S58 (in this supplement).
44. Torres A. Treatment guidelines and outcomes in hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S48-S53 (in this supplement).
45. Perspective on HAP/VAP Clinical Trials. Issues in the design of clinical trials for antibacterial drugs for hospital-acquired pneumonia (HAP) and ventilator-acquired pneumonia (VAP). 2009:128-143. http://www.fda.gov/downloads/ Drugs/News Events/UCM169944.pdf. Accessed 1 March 2010.
46. Stevens RM, Teres D, Skillman J, Feingold DS. Pneumonia in an intensive care unit: a 30 month experience. Arch Intern Med 1974; 134:106-111.
47. Smith IM, Champion MC, Hazard EC, Lowry L, Leaverton PE. Single and combined antibiotics in the treatment of Pseudomonas aeruginosa infections: progress in antimicrobial and anticancer chemotherapy. In: Proceedings of the 6th International Congress of Chemotherapy. Baltimore, MD: University Park Press, 1970; 1:718-724
48. Kassowitz KE, Muscato GH. The long range effect of antibacterial therapy on pneumonia, empyema, bronchiectasis and pulmonary abscess: an analysis of incidence and mortality in 74,489 admissions to a children's hospital in twenty years. Chest 1952; 21:161-173.
49. Glew RH, Moellering RC Jr, Kunz LJ. Infections with Acinetobacter calcoaceticus (Her-ellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) 1977; 56:79-97.
50. Singer M, Nambiar S, Valappil T, Higgins K, Gitterman S. Historical and regulatory perspective on the treatment effect of antibacterial drugs for community-acquired pneumonia. Clin Infect Dis 2008; 47(Suppl 3): S216-S224.
51. Fleming TR, Powers JH. Issues in noninfer-iority trials: the evidence in community-acquired pneumonia. Clin Infect Dis 2008; 47(Suppl 3):S108-S120.
52. Maroko R, Cooper A, Dukart G, Dartois N, Gandjini H. Results of phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/cilastatin (IMI) regimen in treatment of patients (Pts) with hospital-acquired pneumonia (HAP). In: Program and abstracts of the 47th Interscience Convention on Antimicrobial Agents and Chemotherapy (Chicago). 2007. L730.
53. Curcio D, Fernandez F, Vergara J, Vazquez W, Luna CM. Late onset ventilator-associated pneumonia due to multidrug-resistant Aci-netobacter spp.: experience with tigecycline. J Chemother 2009; 21:58-62.
54. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseu-domonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011.
55. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imi-penem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33: 1162-1167.
56. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg Infect (Larchmt) 2008; 9:153-160.
57. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43(Suppl 2):S89-S94.
58. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31: 1058-1065.
59. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E10, Choice of control group and related issues in clinical trials. 1998:7. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125912.pdf. Accessed 1 March 2010.
60. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E10, Choice of control group and related issues in clinical trials. 1998:30. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125912.pdf. Accessed 1 March 2010.
61. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E10, Choice of control group and related issues in clinical trials. 1998:32. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm125912.pdf. Accessed 1 March 2010.
62. Barriere S. Challenges in the design and conduct of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective. Clin Infect Dis 2010; 51(Suppl 1):S4-S9 (in this supplement).
63. Talbot GH. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S144-S149 (in this supplement).
64. Vidaur L, Planas K, Sierra R, et al. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest 2008; 133:625-632.
65. Shorr AF, Cook D, Jiang X, Muscedere J, Heyland D. Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. J Crit Care 2008; 23:64-73.
66. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676-682.
67. Guidance for Industry. Community-acquired bacterial pneumonia: developing drugs for treatment. US Food and Drug Administration. Center for Drug Evaluation and Research. 2007:24-25. http://www.fda.gov/downloads/Drugs/ GuidanceCompliance-RegulatoryInformation/Guidances/ucm123686.pdf. Accessed 1 March 2010.
68. Powers J. Primary and secondary and composite endpoints. In: Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community-Acquired Pneumonia: A Workshop Co-sponsored by the IDSA and FDA (Silver Spring, MD). 2008.
69. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Stat Med 2002;21: 2959-2970.
70. Wunderink RG. Surrogate markers and mi-crobiologic end points. Clin Infect Dis 2010; 51(Suppl 1):S126-S130 (in this supplement).
71. Sterling TR, Ho EJ, Brehm WT, Kirkpatrick MB. Diagnosis and treatment of ventilator-associated pneumonia-impact on survival: a decision analysis. Chest 1996; 110: 1025-1034.
72. Fagon JY, Chastre J, Hance AJ, et al. Detection of nosocomial lung infection in ventilated patients: use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis 1988; 138: 110-116.
73. Wunderink RG. Clinical criteria in the diagnosis of ventilator-associated pneumonia. Chest 2000; 117:191S-194S.
74. Klompas M. Does this patient have ventilator-associated pneumonia? JAMA 2007; 297: 1583-1593.
75. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121-1129.
76. Shorr A. Ventilator-associated pneumonia: the Clinical Pulmonary Infection Score as a surrogate for diagnostics and outcome. Clin Infect Dis 2010; 51(Suppl 1):S131-S135 (in this supplement).
77. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-511.
78. Croce MA, Swanson JM, Magnotti LJ, et al. The futility of the clinical pulmonary infection score in trauma patients. J Trauma 2006; 60:523-527; discussion 527-528.
79. Pham TN, Neff MJ, Simmons JM, Gibran NS, Heimbach DM, Klein MB. The clinical pulmonary infection score poorly predicts pneumonia in patients with burns. J Burn Care Res 2007; 28:76-79.
80. Napolitano L. Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S67-S80 (in this supplement).
81. Goldberg AE, Malhotra AK, Riaz OJ, et al. Predictive value of broncho-alveolar lavage fluid Gram's stain in the diagnosis of ventilator-associated pneumonia: a prospective study. J Trauma 2008; 65:871-876; discussion 876-878.
82. Panda A, McArdle J. Value of gram stain examination of respiratory tract samples for the accurate diagnosis of ventilator-associated pneumonia. In: Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting (Washington DC). 2008. Abstract K-497.
83. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355:2619-2630.
84. Niederman M. The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S93-S99 (in this supplement).
85. Chastre J. Diagnostics techniques and procedures for establishing the microbial etiology of ventilator-associated pneumonia for clinical trials: the pros of quantitative cultures. Clin Infect Dis 2010; 51(Suppl 1): S54-S58 (in this supplement).
86. Kollef MH. Diagnosis of ventilator-associated pneumonia. N Engl J Med 2006; 355: 2691-2693.
87. Kollef MH, Bock KR, Richards RD, Hearns ML. The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Ann Intern Med 1995; 122:743-748.
88. Bregeon F, Papazian L, Thomas P, et al. Diagnostic accuracy of protected catheter sampling in ventilator-associated bacterial pneumonia. Eur Respir J 2000; 16:969-975.
89. Campbell GD Jr. Blinded invasive diagnostic procedures in ventilator-associated pneumonia. Chest 2000; 117:207S-211S.
90. Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975; 50:339-344.
91. Van Scoy RE. Bacterial sputum cultures: a clinician's viewpoint. Mayo Clin Proc 1977; 52:39-41.
92. Geckler RW, Gremillion DH, McAllister CK, Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and tran-stracheal aspirates. J Clin Microbiol 1977; 6: 396-399.
93. Ambrose PG. Pharmacokinetic-pharmaco-dynamic considerations in the design of hospital-acquired or ventilator-associated pneumonia studies: look before you leap! Clin Infect Dis 2010; 51(Suppl 1):S103-S110 (in this supplement).
94. Abrahamian FM, Deblieux PM, Emerman CL, et al. Health care-associated pneumonia: identification and initial management in the ED. Am J Emerg Med 2008; 26:1-11.
95. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-3862.
96. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28:825-831.
97. Craven D. Ventilator-associated tracheo-bronchitis and pneumonia: thinking outside the box. Clin Infect Dis 2010; 51(Suppl 1): S59-S66 (in this supplement).
98. Bradley J. Considerations unique to pediatrics for clinical trial design in health care-associated pneumonia and ventilator-associated pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S136-S143 (in this supplement).
99. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46:1142-1151.
100. Carlet J, Fabry J, Amalberti R, Degos L. The "zero risk" concept for hospital-acquired infections: a risky business! Clin Infect Dis 2009; 49:747-749.
101. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-1081.